Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.10
INNT's Cash-to-Debt is ranked lower than
65% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. INNT: 1.10 )
Ranked among companies with meaningful Cash-to-Debt only.
INNT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.09 Max: 78.16
Current: 1.1
0
78.16
Debt-to-Equity 13.62
INNT's Debt-to-Equity is ranked lower than
64% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. INNT: 13.62 )
Ranked among companies with meaningful Debt-to-Equity only.
INNT' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.78  Med: -0.63 Max: 13.62
Current: 13.62
-1.78
13.62
Debt-to-EBITDA -0.29
INNT's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. INNT: -0.29 )
Ranked among companies with meaningful Debt-to-EBITDA only.
INNT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.77  Med: -0.51 Max: -0.01
Current: -0.29
-0.77
-0.01
Piotroski F-Score: 4
Altman Z-Score: -4249.70
Beneish M-Score: -3511.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA % -1658.22
INNT's ROA % is ranked lower than
98% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. INNT: -1658.22 )
Ranked among companies with meaningful ROA % only.
INNT' s ROA % Range Over the Past 10 Years
Min: -2883.6  Med: -177.89 Max: -111.13
Current: -1658.22
-2883.6
-111.13
ROC (Joel Greenblatt) % -118583.57
INNT's ROC (Joel Greenblatt) % is ranked lower than
98% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. INNT: -118583.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INNT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -118583.57  Med: -8266.96 Max: -1482.38
Current: -118583.57
-118583.57
-1482.38
3-Year Revenue Growth Rate -100.00
INNT's 3-Year Revenue Growth Rate is ranked lower than
85% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. INNT: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INNT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -47.9 Max: 4.2
Current: -100
-100
4.2
3-Year EBITDA Growth Rate 62.50
INNT's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. INNT: 62.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INNT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.4  Med: 24.05 Max: 62.5
Current: 62.5
-14.4
62.5
GuruFocus has detected 4 Warning Signs with Innovate Biopharmaceuticals Inc INNT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INNT's 30-Y Financials

Financials (Next Earnings Date: 2019-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with INNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:ASX:CPH, TSX:COM, WBO:MSBT, LSE:OPTI, TPE:1762, NAS:AXSM, HKSE:03839, XMCE:IKM, NAS:APVO, XPAR:ALTHX, ROCO:3205, NAS:SPHS, XCNQ:MMJ, LSE:DEST, AMEX:NAVB, AMEX:NBY, ASX:BOT, OSTO:CANTA, LSE:SCLP, NAS:BCLI » details
Traded in other countries:2Q3.Germany,
Headquarter Location:USA
Innovate Biopharmaceuticals Inc is a clinical stage biotechnology company. The company is engaged in developing novel medicines for autoimmune/ inflammatory disease.

Innovate Biopharmaceuticals Inc, formerly known as Monster Digital Inc is a clinical stage biotechnology company. The company is engaged in developing novel medicines for autoimmune/ inflammatory disease. Its products include drug candidates for celiac disease, an unmet need, and ulcerative colitis.

Top Ranked Articles about Innovate Biopharmaceuticals Inc

Innovate Biopharmaceuticals Reports Financing to Initiate the First Phase 3 Clinical Trial in Celiac Disease, Fiscal Year 2018 Earnings and Key Corporate Highlights
Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 19, 2019
Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial
Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 18, 2019
Innovate Biopharmaceuticals Announces Presentation at Cowen’s 39th Annual Health Care Conference in Boston
Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 14, 2019
Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 14, 2019
Innovate Biopharmaceuticals Schedules Conference Call to Provide Corporate and Operational Progress Updates
Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts Focusing on the Molecular Biology and Pharmacology of Larazotide for the 2019 Digestive Disease Week Conference
Innovate Biopharmaceuticals Announces a New Chief Executive Officer and Chief Medical Officer

Ratios

vs
industry
vs
history
Current Ratio 1.04
INNT's Current Ratio is ranked lower than
69% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. INNT: 1.04 )
Ranked among companies with meaningful Current Ratio only.
INNT' s Current Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.55 Max: 2.43
Current: 1.04
0.06
2.43
Quick Ratio 1.04
INNT's Quick Ratio is ranked lower than
66% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. INNT: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
INNT' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.29 Max: 2.43
Current: 1.04
0.04
2.43
Days Inventory 84.91
INNT's Days Inventory is ranked lower than
76% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. INNT: 84.91 )
Ranked among companies with meaningful Days Inventory only.
INNT' s Days Inventory Range Over the Past 10 Years
Min: 54.72  Med: 95.28 Max: 113.04
Current: 84.91
54.72
113.04
Days Payable 2.00
INNT's Days Payable is ranked higher than
98% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. INNT: 2.00 )
Ranked among companies with meaningful Days Payable only.
INNT' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 53 Max: 498409.09
Current: 2
2
498409.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -39.60
INNT's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. INNT: -39.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INNT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -39.6  Med: -26.7 Max: -13.8
Current: -39.6
-39.6
-13.8

Valuation & Return

vs
industry
vs
history

More Statistics

EPS (TTM) $ -926.29
Volatility453.31%
52-Week Range $1.70 - 50.50
Shares Outstanding (Mil)30.27

Analyst Estimate

Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.97 -1.51
EPS without NRI ($) -0.97 -1.51
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}